Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia. Issue 1 (24th January 2022)

• Record Type: Journal Article
• Authors: Reisi, Nahid; Esmaeil, Nafiseh; Gharagozloo, Marjan; Moayedi, Behjat
• Is Part Of: Clinical case reports. Volume 10:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-24
• Subjects: ferritin -- iron chelator -- liver -- milk thistle -- silymarin -- thalassemia; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.5293
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Abnormal iron accumulation in vital organs is one of the major complications of β‐thalassemia intermedia (β‐TI). Silymarin, a flavonolignan isolated from Silybum marianum, significantly decreases the serum ferritin levels of β‐TI patients. This finding suggests silymarin as a safe and effective natural iron‐chelating agent for the treatment of iron‐overloaded conditions. Abstract : This is the first report showing the iron‐chelating effects of silymarin monotherapy in β‐thalassemia, suggesting that silymarin can be used safely and effectively in the treatment of iron‐overloaded conditions.